Oncoshot receives funding to additional increase in India, Australia
Singaporean medical startup Oncoshot has scored an undisclosed funding via a pre-Sequence A funding spherical led by Biofurmis and Qure.ai investor MassMutual Ventures.
Primarily based on a press launch, the funding will assist the corporate’s additional enlargement into India and Australia.
There are 4 hospital networks in India and a few networks of over 20 hospitals in Oceania which can be about to arrange their respective nationwide public-private scientific trial ecosystems like Singapore’s Undertaking EISE. The latter makes use of Oncoshot’s scientific trial matching platform to attach most cancers sufferers, healthcare professionals, and pharmaceutical and biotechnology firms.
It’s mentioned that scientific trials worldwide lose round $35 billion every year as a result of inefficient processes in most cancers analysis and affected person recruitment.
Oncoshot has developed an answer to such points by enhancing the well being data of scientific companions via AI and machine studying. Its federated knowledge system securely hosts crucial and delicate affected person knowledge inside hospital premises and supplies full safety, entry and management of analyses and insights to hospital directors.
Well being data web site Happiest Well being goes dwell in India
Indian IT service and consultancy agency Happiest Minds Applied sciences has launched a brand new on-line repository of well being and wellness data and knowledge.
Referred to as Happiest Well being, the web site goals to offer “in-depth, credible, and reliable” data on well being and wellness, in line with a press assertion.
It should educate its viewers with breakthroughs and developments in well being and wellness, sourced from new analysis and research from associate international institutes. The portal may also put a highlight on new instruments for early analysis, in addition to consumer tales and feedback.
Furthermore, a panel of docs and wellness specialists will contribute visitor essays and articles that provide distinctive views and attention-grabbing medical experiences.
“By Happiest Well being, we need to construct the significance of built-in medication, present useful data via specialists on early analysis and evidence-based therapies and achieve this with empathy and fervour,” mentioned Happiest Well being chairman Ashok Soota.
By subsequent yr, the web site will publish written and video content material in regional languages to cater to lower-tier cities in India. Happiest Well being may also launch a podcast, internet collection, and audio content material quickly.
Medical trials in India affirm AI’s effectiveness in detecting referable glaucoma
Indian medical system maker Remidio Revolutionary Options has reported constructive outcomes from separate scientific trials of its AI answer in detecting referable glaucoma.
Remidio gives an built-in screening answer for referable glaucoma, a stage whereby the illness can nonetheless be higher managed via remedy. It consists of a fundus on cellphone, a retinal imaging system, and an AI algorithm for offline inferencing. The Medios Referable Glaucoma AI detects structural modifications within the optic nerve head and surrounding retinal nerve fibre layer.
In line with a press assertion, the entire detection course of solely takes 15 seconds.
The corporate just lately partnered with two native eye hospitals, Aravind Eye Hospital in Pondicherry and Narayana Nethralaya (NN) in Bangalore, to check its screening answer.
Within the scientific trial at NN, the AI algorithm was discovered to realize a excessive sensitivity of 93.5% and excessive specificity of 85.4% in detecting referable glaucoma whereas early outcomes from the scientific trial at Aravind confirmed the algorithm to additionally obtain excessive sensitivity and specificity of 91.3% and 91.67%, respectively.
The corporate famous that whereas remedy choices for managing referable glaucoma exist, easy screening checks are tough to seek out. At current, glaucoma specialists are nonetheless conducting a collection of advanced investigations utilizing a number of units to identify referable glaucoma.
“Promising outcomes present that our AI can empower healthcare staff and basic ophthalmologists to make an goal screening analysis, particularly at centres missing refined diagnostic tools,” mentioned Dr Divya Rao, medical director and head of AI at Remidio.